$PBIO
PRESSURE BIOSCIENCES INC Stock $pbio

$pbio Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000149315222023029 Filed on August 15, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$144.0K	$498.1K	$480.0K
YoY Change	-72.21%	-18.19%	-14.27%
Cost Of Revenue	$126.2K	$302.1K	$314.4K
YoY Change	-51.12%	5.4%	38.93%
Gross Profit	$17.83K	$196.0K	$165.6K
YoY Change	-93.15%	-39.18%	-50.35%
Gross Profit Margin	12.38%	39.35%	34.51%
Selling, General & Admin	$1.119M	$924.9K	$970.4K
YoY Change	-8.3%	29.88%	-12.48%
% of Gross Profit	6275.28%	471.9%	585.82%
Research & Development	$262.4K	$172.7K	$281.6K
YoY Change	-7.17%	-32.66%	-6.12%
% of Gross Profit	1471.59%	88.13%	170.0%
Depreciation & Amortization	$5.780K	$27.11K	$35.10K
YoY Change	-78.78%	-6.84%	29.09%
% of Gross Profit	32.42%	13.83%	21.19%
Operating Expenses	$1.381M	$1.098M	$1.252M
YoY Change	-8.09%	13.32%	-11.13%
Operating Profit	-$1.363M	-$901.6K	-$1.086M
YoY Change	9.72%	39.5%	1.04%
Interest Expense	$2.034M	$1.836M	-$2.560M
YoY Change	-158.25%	-47.94%	-46.4%
% of Operating Profit
Other Income/Expense, Net	-$3.099M	-$2.015M	-$3.510K
YoY Change	-5211.13%	-50.85%	158.09%
Pretax Income	-$4.462M	-$2.916M	-$4.240M
YoY Change	-9.87%	-38.54%	-35.54%
Income Tax
% Of Pretax Income
Net Earnings	-$4.462M	-$2.916M	-$4.240M
YoY Change	-9.87%	-38.54%	-35.54%
Net Earnings / Revenue	-3098.09%	-585.45%	-883.27%
Basic Earnings Per Share	-$0.44	-$0.32	-$0.48
Diluted Earnings Per Share	-$400.9K	-$278.7K	-$437.3K
COMMON SHARES
Basic Shares Outstanding	9.074M shares	10.46M shares	9.695M shares
Diluted Shares Outstanding	11.13M shares	10.46M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$230.9K	$121.6K	$118.8K
YoY Change	-65.21%	160.71%	135.11%
Cash & Equivalents	$230.9K	$121.6K	$118.8K
Short-Term Investments
Other Short-Term Assets	$218.5K	$228.3K	$184.9K
YoY Change	-64.82%	4.15%	-31.92%
Inventory	$1.387M	$1.356M	$1.361M
Prepaid Expenses
Receivables	$166.3K	$316.8K	$291.9K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$2.002M	$2.022M	$1.956M
YoY Change	-23.57%	45.74%	41.13%
LONG-TERM ASSETS
Property, Plant & Equipment	$111.9K	$101.8K	$472.5K
YoY Change	-36.3%	-48.39%	114.06%
Goodwill
YoY Change
Intangibles	$360.6K	$360.6K
YoY Change
Long-Term Investments	$51.93K	$60.60K	$79.11K
YoY Change	-53.86%	-77.93%	-80.66%
Other Assets
YoY Change
Total Long-Term Assets	$838.0K	$864.7K	$933.9K
YoY Change	17.41%	-5.91%	-15.0%
TOTAL ASSETS
Total Short-Term Assets	$2.002M	$2.022M	$1.956M
Total Long-Term Assets	$838.0K	$864.7K	$933.9K
Total Assets	$2.840M	$2.887M	$2.890M
YoY Change	-14.8%	25.16%	16.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$608.1K	$552.7K	$665.2K
YoY Change	45.46%	-12.11%	-6.48%
Accrued Expenses	$2.800M	$2.533M	$2.439M
YoY Change	25.23%	-4.52%	-7.74%
Deferred Revenue
YoY Change
Short-Term Debt	$18.83M	$17.59M	$15.80M
YoY Change	46.32%	41.21%	38.01%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$32.29M	$29.75M	$27.25M
YoY Change	42.42%	24.18%	22.02%
LONG-TERM LIABILITIES
Long-Term Debt	$150.0K	$150.0K	$150.0K
YoY Change	-71.54%	-71.54%	-71.54%
Other Long-Term Liabilities	$171.9K	$203.0K	$235.8K
YoY Change	55.4%	58.52%	56.06%
Total Long-Term Liabilities	$321.9K	$353.0K	$385.8K
YoY Change	-49.52%	-46.12%	-43.11%
TOTAL LIABILITIES
Total Short-Term Liabilities	$32.29M	$29.75M	$27.25M
Total Long-Term Liabilities	$321.9K	$353.0K	$385.8K
Total Liabilities	$32.62M	$30.10M	$27.64M
YoY Change	39.91%	22.31%	20.1%
SHAREHOLDERS EQUITY
Retained Earnings	-$128.9M	-$124.0M
YoY Change
Common Stock	$122.2K	$107.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$29.78M	-$27.21M	-$24.75M
YoY Change
Total Liabilities & Shareholders Equity	$2.840M	$2.887M	$2.890M
YoY Change	-14.8%	25.16%	16.31%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$4.462M	-$2.916M	-$4.240M
YoY Change	-9.87%	-38.54%	-35.54%
Depreciation, Depletion And Amortization	$5.780K	$27.11K	$35.10K
YoY Change	-78.78%	-6.84%	29.09%
Cash From Operating Activities	-$1.053M	-$1.242M	-$756.3K
YoY Change	-47.17%	45.47%	-38.86%
INVESTING ACTIVITIES
Capital Expenditures	-$15.86K	-$3.750K	-$1.140K
YoY Change	2837.04%		-71.21%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$15.86K	-$3.750K	-$1.140K
YoY Change	2837.04%		-71.21%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.178M	1.248M	743.9K
YoY Change	-54.87%	46.91%	-41.56%
NET CHANGE
Cash From Operating Activities	-1.053M	-1.242M	-756.3K
Cash From Investing Activities	-15.86K	-3.750K	-1.140K
Cash From Financing Activities	1.178M	1.248M	743.9K
Net Change In Cash	109.3K	2.770K	-13.51K
YoY Change	-82.28%	-170.84%	-142.23%
FREE CASH FLOW
Cash From Operating Activities	-$1.053M	-$1.242M	-$756.3K
Capital Expenditures	-$15.86K	-$3.750K	-$1.140K
Free Cash Flow	-$1.037M	-$1.238M	-$755.1K
YoY Change	-47.95%	45.03%	-38.76%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0000830656
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q4	us-gaap	Due To Other Related Parties Classified Current DueToOtherRelatedPartiesClassifiedCurrent		usd
CY2022Q2	PBIO	Deemed Dividends On Beneficial Conversion Feature DeemedDividendsOnBeneficialConversionFeature		usd
CY2021Q2	PBIO	Deemed Dividends On Beneficial Conversion Feature DeemedDividendsOnBeneficialConversionFeature		usd
	PBIO	Deemed Dividends On Beneficial Conversion Feature DeemedDividendsOnBeneficialConversionFeature		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock		usd
	PBIO	Noncash Cumulative Effect Period Of Adoption Adjustment NoncashCumulativeEffectPeriodOfAdoptionAdjustment		usd
	PBIO	Discount Due To Beneficial Conversion Feature DiscountDueToBeneficialConversionFeature		usd
	PBIO	Non Cash Deemed Dividendbeneficial Conversion Feature NonCashDeemedDividendbeneficialConversionFeature		usd
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1		usd
CY2022Q2	PBIO	Stock Issued During Period Value Conversion Of Convertible Securities Conversion Of Preferred Stock For Common Stock StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesConversionOfPreferredStockForCommonStock		usd
CY2022Q2	PBIO	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour		usd
CY2022Q2	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38185
	dei	Entity Registrant Name EntityRegistrantName	PRESSURE BIOSCIENCES, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	MA
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-2652826
	dei	Entity Address Address Line1 EntityAddressAddressLine1	14 Norfolk Avenue
	dei	Entity Address City Or Town EntityAddressCityOrTown	South Easton
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02375
	dei	City Area Code CityAreaCode	(508)
	dei	Local Phone Number LocalPhoneNumber	230-1828
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	9074069	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	121569	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	132311	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	316796	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	154746	usd
CY2022Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	342496	usd
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	342496	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	1355676	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Inventory Net InventoryNet	1147554	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	228254	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	422617	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	2022295	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	1857228	usd
CY2022Q2	us-gaap	Equity Method Investments EquityMethodInvestments	60604	usd
CY2021Q4	us-gaap	Equity Method Investments EquityMethodInvestments	59976	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	101798	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	115846	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	341681	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	395565	usd
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	360577	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	403846	usd
CY2022Q2	us-gaap	Assets Assets	2886955	usd
CY2021Q4	us-gaap	Assets Assets	2832461	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	552691	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	527924	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	237102	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	117680	usd
CY2022Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2157575	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1955672	usd
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	9036299	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	7757217	usd
CY2022Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	31851	usd
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	37124	usd
CY2022Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	15686451	usd
CY2021Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	12839813	usd
CY2022Q2	PBIO	Other Debt Unamortized Discounts Net OtherDebtUnamortizedDiscountsNet	16900	usd
CY2021Q4	PBIO	Other Debt Unamortized Discounts Net OtherDebtUnamortizedDiscountsNet	0	usd
CY2022Q2	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	1621854	usd
CY2021Q4	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	1256840	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	138691	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	132996	usd
CY2022Q2	PBIO	Other Related Party Debt Unamortized Discount Net OtherRelatedPartyDebtUnamortizedDiscountNet	23646	usd
CY2021Q4	PBIO	Other Related Party Debt Unamortized Discount Net OtherRelatedPartyDebtUnamortizedDiscountNet	0	usd
CY2022Q2	us-gaap	Due To Other Related Parties Classified Current DueToOtherRelatedPartiesClassifiedCurrent	283804	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	29746318	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	24625266	usd
CY2022Q2	us-gaap	Long Term Debt LongTermDebt	150000	usd
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	150000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	202990	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	262569	usd
CY2021Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	3587	usd
CY2022Q2	us-gaap	Liabilities Liabilities	30099308	usd
CY2021Q4	us-gaap	Liabilities Liabilities	25041422	usd
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10703179	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10703179	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9120526	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9120526	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	107033	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	91206	usd
CY2022Q2	PBIO	Warrants To Acquire Common Stock WarrantsToAcquireCommonStock	31974888	usd
CY2021Q2	us-gaap	Costs And Expenses CostsAndExpenses	1255266	usd
	us-gaap	Costs And Expenses CostsAndExpenses	2966066	usd
	us-gaap	Costs And Expenses CostsAndExpenses	2890242	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-901630	usd
CY2021Q4	PBIO	Warrants To Acquire Common Stock WarrantsToAcquireCommonStock	31715154	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	64746760	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	64261048	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-124042132	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-646339	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1987929	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1721441	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	1835589	usd
CY2021Q2	us-gaap	Interest Expense InterestExpense	3526141	usd
	us-gaap	Interest Expense InterestExpense	4414750	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-118277468	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-27212353	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-22208961	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2886955	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2832461	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	498137	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	608927	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	978137	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1168801	usd
CY2022Q2	us-gaap	Revenues Revenues	498137	usd
CY2021Q2	us-gaap	Revenues Revenues	608927	usd
	us-gaap	Revenues Revenues	978137	usd
	us-gaap	Revenues Revenues	1168801	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	302141	usd
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	286660	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	616504	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	512935	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	172726	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	256507	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	454315	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	556450	usd
CY2022Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	129434	usd
CY2021Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	92813	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	195896	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	186141	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	795466	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	619286	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1699351	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1634716	usd
CY2022Q2	us-gaap	Costs And Expenses CostsAndExpenses	1399767	usd
	us-gaap	Interest Expense InterestExpense	8194205	usd
CY2022Q2	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	-18510	usd
CY2021Q2	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	-134477	usd
	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	628	usd
	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	-242380	usd
CY2022Q2	PBIO	Loss On Extinguishment Of Liabilities LossOnExtinguishmentOfLiabilities	-165277	usd
CY2021Q2	PBIO	Loss On Extinguishment Of Liabilities LossOnExtinguishmentOfLiabilities	-498226	usd
	PBIO	Loss On Extinguishment Of Liabilities LossOnExtinguishmentOfLiabilities	-755127	usd
	PBIO	Loss On Extinguishment Of Liabilities LossOnExtinguishmentOfLiabilities	-1223385	usd
CY2022Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	4668	usd
CY2021Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	60012	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	1155	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	58653	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2014708	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4098832	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5168094	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9601317	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2916338	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-4745171	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7156023	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11322758	usd
	PBIO	Deemed Dividends On Beneficial Conversion Feature DeemedDividendsOnBeneficialConversionFeature	57884	usd
CY2022Q2	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	431708	usd
CY2021Q2	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	404171	usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	863857	usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	807386	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3348046	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5149342	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8019880	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12188028	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.90
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.80
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.29
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10462520	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5748711	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10029068	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5312172	shares
	us-gaap	Net Income Loss NetIncomeLoss	-7156023	usd
	us-gaap	Net Income Loss NetIncomeLoss	-11322758	usd
	PBIO	Gain On Loan Forgiveness GainOnLoanForgiveness	10000	usd
	PBIO	Gain On Loan Forgiveness GainOnLoanForgiveness	367039	usd
	PBIO	Noncash Lease Expense Income NoncashLeaseExpenseIncome	53884	usd
	PBIO	Noncash Lease Expense Income NoncashLeaseExpenseIncome	31624	usd
	PBIO	Common Stock And Warrants Issued For Interest And Extension Fees CommonStockAndWarrantsIssuedForInterestAndExtensionFees	1561973	usd
	PBIO	Common Stock And Warrants Issued For Interest And Extension Fees CommonStockAndWarrantsIssuedForInterestAndExtensionFees	4054749	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	62207	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	56291	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1457204	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-3909024	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-755127	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	96557	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	124695	usd
	us-gaap	Debt And Equity Securities Realized Gain Loss DebtAndEquitySecuritiesRealizedGainLoss	628	usd
	us-gaap	Debt And Equity Securities Realized Gain Loss DebtAndEquitySecuritiesRealizedGainLoss	-242380	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	185261	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	238512	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	162050	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	498538	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	208122	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-100672	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-194363	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-95775	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	24767	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-143110	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	119422	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	2932	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-53884	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-31624	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1081750	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1415688	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1998192	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2090727	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4890	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3962	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4890	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3962	usd
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	100000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	17443	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	14773	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	2209750	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	2598250	usd
	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	1288100	usd
	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	1183188	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	464500	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	171600	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	865367	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	1200996	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	209000	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	153000	usd
	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	913086	usd
	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	591041	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1992340	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2122774	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10742	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	28085	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	132311	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	18540	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	121569	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	46625	usd
	us-gaap	Interest Paid Net InterestPaidNet	515210	usd
	us-gaap	Interest Paid Net InterestPaidNet	383403	usd
	us-gaap	Stock Issued1 StockIssued1	178328	usd
	us-gaap	Stock Issued1 StockIssued1	112877	usd
	PBIO	Discount From Warrants Issued With Debt DiscountFromWarrantsIssuedWithDebt	87436	usd
	PBIO	Discount From Warrants Issued With Debt DiscountFromWarrantsIssuedWithDebt	1068842	usd
	PBIO	Common Stock Issued In Lieu Of Cash For Dividend CommonStockIssuedInLieuOfCashForDividend	215277	usd
	PBIO	Common Stock Issued In Lieu Of Cash For Dividend CommonStockIssuedInLieuOfCashForDividend	114298	usd
	PBIO	Noncash Cumulative Effect Period Of Adoption Adjustment NoncashCumulativeEffectPeriodOfAdoptionAdjustment	473027	usd
	PBIO	Noncash Preferred Stock Dividends NoncashPreferredStockDividends	863857	usd
	PBIO	Noncash Preferred Stock Dividends NoncashPreferredStockDividends	807386	usd
	PBIO	Conversion Of Debt Into Common Stock ConversionOfDebtIntoCommonStock	350500	usd
	PBIO	Conversion Of Debt Into Common Stock ConversionOfDebtIntoCommonStock	349350	usd
	PBIO	Discount Due To Beneficial Conversion Feature DiscountDueToBeneficialConversionFeature	566847	usd
	PBIO	Non Cash Deemed Dividendbeneficial Conversion Feature NonCashDeemedDividendbeneficialConversionFeature	57884	usd
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	44	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-22208961	usd
CY2022Q1	PBIO	Cumulative Effect Period Of Adoption Adjustment CumulativeEffectPeriodOfAdoptionAdjustment	-473027	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	64483	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	432149	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	77700	usd
CY2022Q1	PBIO	Issuance Of Common Stock Warrants For Services IssuanceOfCommonStockWarrantsForServices	39761	usd
CY2022Q1	PBIO	Warrants Issued For Debt Extension WarrantsIssuedForDebtExtension	132537	usd
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	472900	usd
CY2022Q1	PBIO	Issuance Of Common Stock For Dividends Paidinkind IssuanceOfCommonStockForDividendsPaidinkind	64256	usd
CY2022Q1	PBIO	Issuance Of Common Stock For Interest Paidinkind IssuanceOfCommonStockForInterestPaidinkind	1173458	usd
	PBIO	Debt Instrument Discount Percentage Of Stock Price DebtInstrumentDiscountPercentageOfStockPrice	0.25	pure
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	350500	usd
	us-gaap	Debt Instrument Convertible Stock Price Trigger DebtInstrumentConvertibleStockPriceTrigger	2.50
CY2022Q1	PBIO	Stock Issued With Debt StockIssuedWithDebt	142480	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	87436	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4239685	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-24748311	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	32074	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	17443	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	431708	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	67800	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	191303	usd
CY2022Q2	PBIO	Issuance Of Common Stock For Dividends Paidinkind IssuanceOfCommonStockForDividendsPaidinkind	151021	usd
CY2022Q2	PBIO	Issuance Of Common Stock For Interest Paidinkind IssuanceOfCommonStockForInterestPaidinkind	388515	usd
CY2022Q2	PBIO	Stock Issued With Debt StockIssuedWithDebt	35848	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-2916338	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-27212353	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-16917592	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	61237	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	14773	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	403215	usd
CY2021Q1	PBIO	Issuance Of Common Stock Warrants For Interest Paidinkind IssuanceOfCommonStockWarrantsForInterestPaidinkind	600298	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	238512	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	53777	usd
CY2021Q1	PBIO	Preferred Stock Offering PreferredStockOffering	100000	usd
CY2021Q1	PBIO	Beneficial Conversion Option On Convertible Preferred Stock BeneficialConversionOptionOnConvertiblePreferredStock	57884	usd
CY2021Q1	PBIO	Deemed Dividend On Convertible Preferred Stock DeemedDividendOnConvertiblePreferredStock	-57884	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	118000	usd
CY2021Q1	PBIO	Issuance Of Common Stock For Interest Paidinkind IssuanceOfCommonStockForInterestPaidinkind	2021780	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	162654	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-6577587	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-20527363	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	63458	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	404171	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	513070	usd
CY2021Q2	PBIO	Issuance Of Common Stock For Interest Paidinkind IssuanceOfCommonStockForInterestPaidinkind	1432671	usd
CY2021Q2	PBIO	Issuance Of Common Stock For Dividends Paidinkind IssuanceOfCommonStockForDividendsPaidinkind	114298	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	231250	usd
CY2021Q2	PBIO	Stock Issued With Debt StockIssuedWithDebt	112877	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	906188	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-4745171	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-22302893	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_846_eus-gaap--UseOfEstimates_zrFeEUvcBiTi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zFMftuptWyPb">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s consolidated financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America, which require the use of estimates, judgements and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the periods presented. Global concerns about the COVID-19 pandemic have adversely affected, and we expect will continue to adversely affect, our business, financial condition and results of operations including the estimates and assumptions made by management. Significant estimates and assumptions include valuations of share-based awards, investments in equity securities and intangible asset impairment. Actual results could differ from the estimates, and such differences may be material to the Company’s consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	498000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	609000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	978000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1169000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	498000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	609000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	978000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1169000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	498000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	609000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	978000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1169000	usd
CY2022Q2	us-gaap	Accounts Receivable Billed For Long Term Contracts Or Programs AccountsReceivableBilledForLongTermContractsOrPrograms	317000	usd
CY2021Q4	us-gaap	Accounts Receivable Billed For Long Term Contracts Or Programs AccountsReceivableBilledForLongTermContractsOrPrograms	155000	usd
CY2022Q2	us-gaap	Deferred Revenue DeferredRevenue	32000	usd
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	41000	usd
CY2022Q2	us-gaap	Extended Product Warranty Accrual ExtendedProductWarrantyAccrual	32000	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zK7pmNFv8Ba" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86F_zQSRps2qOMt7">Concentrations</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Credit Risk</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents, and trade receivables. We have cash investment policies which, among other things, limit investments to investment-grade securities. We perform ongoing credit evaluations of our customers, and the risk with respect to trade receivables is further mitigated by the fact that many of our customers are government institutions, large pharmaceutical and biotechnology companies, and academic laboratories.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--FairValueConcentrationOfRiskTextBlock_zUeqL0kPQpNl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table illustrates the level of concentration as a percentage of total revenues during the three and six months ended June 30, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B5_z7UnWrhgWA99" style="display: none">Schedule of Customer Concentration Risk Percentage</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="6" style="text-align: center">For the Three Months Ended</td><td> </td> <td> </td> <td colspan="6" style="text-align: center">For the Six Months Ended</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">June 30,</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">June 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td> <td style="padding-bottom: 1.5pt"/></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: left">Top Five Customers</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zk8uLlmgsvoe" style="width: 12%; text-align: right" title="Concentration credit risk percentage">69</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zZGXTiQ5nHVc" style="width: 12%; text-align: right" title="Concentration credit risk percentage">50</td><td style="width: 1%; text-align: left">%</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_98E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zKrzZVk4xP57" style="text-align: right; width: 12%">61</td> <td style="width: 1%">%</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td id="xdx_981_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zCwQ0vOhKdt2" style="text-align: right; width: 12%">50</td> <td style="width: 1%">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Federal Agencies</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zDp05rEcPOZb" style="text-align: right" title="Concentration credit risk percentage">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210401__20210630__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zcR1e7yER203" style="text-align: right" title="Concentration credit risk percentage">14</td><td style="text-align: left">%</td> <td> </td> <td> </td> <td id="xdx_984_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ziHlls9bEi9j" style="text-align: right">0</td> <td>%</td> <td> </td> <td> </td> <td id="xdx_98C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20210630__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zzZq6vdqjEqf" style="text-align: right">8</td> <td>%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of June 30, 2022 and December 31, 2021. The Top Five Customers category may include federal agency receivable balances if applicable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">June 30,<br/> 2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31,<br/> 2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Top Five Customers</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zEVjrkMGOZJ8" style="width: 16%; text-align: right" title="Concentration credit risk percentage">92</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--TopFiveCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zSVOwNgbNLtd" style="width: 16%; text-align: right" title="Concentration credit risk percentage">82</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Federal Agencies</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zOx2Jay5yoQe" style="text-align: right" title="Concentration credit risk percentage">0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--FederalAgenciesMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zgv4TPC76VBi" style="text-align: right" title="Concentration credit risk percentage">5</td><td style="text-align: left">%</td></tr> </table> <p id="xdx_8A9_zJ01muiDyX8f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2021Q2	us-gaap	Share Based Compensation ShareBasedCompensation	63458	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	96557	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	124695	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3348046	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5149342	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8019880	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12188028	usd
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10462520	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5748711	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10029068	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5312172	shares
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.90
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.80
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.29
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	32842695	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	30719832	shares
CY2022Q2	PBIO	Forfeiture Rate ForfeitureRate	0.05	pure
CY2022Q2	us-gaap	Share Based Compensation ShareBasedCompensation	32074	usd
CY2022Q2	us-gaap	Share Based Compensation ShareBasedCompensation	32074	usd
CY2021Q2	us-gaap	Share Based Compensation ShareBasedCompensation	63458	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	96557	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	124695	usd
CY2022Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	60604	usd
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	59976	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	115551	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	149299	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	64393	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	66969	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	51778	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	447990	usd
	us-gaap	Debt Instrument Convertible Stock Price Trigger DebtInstrumentConvertibleStockPriceTrigger	2.50
	us-gaap	Debt Instrument Convertible Stock Price Trigger DebtInstrumentConvertibleStockPriceTrigger	2.50
CY2022Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
CY2022Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
	us-gaap	Debt Instrument Convertible Conversion Ratio1 DebtInstrumentConvertibleConversionRatio1	0.10	pure
CY2022Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	2.50
	PBIO	Debt Default Convertible Conversion Ratio DebtDefaultConvertibleConversionRatio	0.75	pure
CY2021Q4	us-gaap	Convertible Debt ConvertibleDebt	12839813	usd
	PBIO	Cumulative Effect Period Of Adoption Adjustment Related To Convertible Debt CumulativeEffectPeriodOfAdoptionAdjustmentRelatedToConvertibleDebt	473027	usd
	PBIO	Issuance Of Convertible Debt Face Value IssuanceOfConvertibleDebtFaceValue	2624738	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	414988	usd
	PBIO	Debt Discount From Shares And Warrants Issued With Debt DebtDiscountFromSharesAndWarrantsIssuedWithDebt	-265764	usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt	865367	usd
	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	68159	usd
	PBIO	Accretion Of Interest And Amortization Of Debt Discount To Interest Expense AccretionOfInterestAndAmortizationOfDebtDiscountToInterestExpense	1363151	usd
CY2022Q2	us-gaap	Convertible Debt ConvertibleDebt	15686451	usd
CY2022Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	15686451	usd
CY2022Q2	us-gaap	Due From Related Parties DueFromRelatedParties	42308	usd
CY2019Q4	us-gaap	Debt Instrument Description DebtInstrumentDescription	On October 1, 2019, the Company and the holder of the $170,000 non-convertible loan issued in May 2017 agreed to extend the term of the loan to December 31, 2019. The Company agreed to issue 1,200 shares of its common stock per month while the note remains outstanding. The note will continue to earn 10% annual interest.
CY2021	PBIO	Debt Instrument Purchase Price DebtInstrumentPurchasePrice	525000	usd
CY2021	PBIO	Debt Instrument Purchased Amount DebtInstrumentPurchasedAmount	686250	usd
CY2021Q4	PBIO	Debt Instrument Outstanding Balance DebtInstrumentOutstandingBalance	398910	usd
CY2021Q4	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	8500	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	17540209	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	17308567	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	230000	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	25279	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	149172	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	17595758	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	17475939	shares

Files In Submission

Name	View Source	Status
0001493152-22-023029-index-headers.html	Edgar Link	pending
0001493152-22-023029-index.html	Edgar Link	pending
0001493152-22-023029.txt	Edgar Link	pending
0001493152-22-023029-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pbio-20220630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
pbio-20220630_cal.xml	Edgar Link	unprocessable
pbio-20220630_lab.xml	Edgar Link	unprocessable
pbio-20220630_pre.xml	Edgar Link	unprocessable
pbio-20220630_def.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PBIO
PRESSURE BIOSCIENCES INC Stock $pbio

2022 Q3 Form 10-Q Financial Statement

#000149315222023029 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PBIO PRESSURE BIOSCIENCES INC Stock $pbio

2022 Q3 Form 10-Q Financial Statement

#000149315222023029 Filed on August 15, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PBIO
PRESSURE BIOSCIENCES INC Stock $pbio